Belimumab

A4DAB037 | Immune-mediated / inflammatory disorders | Approved
TNFSF13B/CD257/BAFF
G1 / IgG1
Assistance Publique Hopitaux de Paris Cancer Trials Australia GlaxoSmithKline Hospital for Special Surgery Human Genome Sciences North Shore-Long Island Jewish Health System University of Alabama at Birmingham University of Pennsylvania University of Wisconsin-Madison Washington University School of Medicine Cambridge Antibody Technology
Approved
Whole mAb
GSK1550188 GSK-1550188 HGS-1006 HGS1006
['6.5', '6']
IMGT PubChem (131283241) PubChem (135353783) PubChem (178103469) PubChem (329976975) PubChem (347910378) PubChem (354355056) PubChem (441071577) PubChem (464013611) PubChem (468568983) PubChem (468808490) PubChem (472219954) PubChem (472422612) PubChem (480409562) PubChem (481101535) PubChem (486489711) PubChem (498138060) PubChem (519990320) Thera-SAbDab YAbS
Avg A4D Score
-0.7071
Score Range
-0.73 to -0.69
Structures
8
Avg. A4D Score per Structure
pH at Min / Max Aggregation Propensity

Associated Structural Profiles Level 2

Structure ID Source PDB Seq. Identity Avg. A4D Score pH (Min Agg.) pH (Max Agg.) Score CDR Score non-CDR
A4DAB037_6fxn_D_E 6fxn 100% -0.6998 6.5 4.0 -0.1977 -0.77
A4DAB037_5y9k_H_L 5y9k 100% -0.6999 6.5 4.0 -0.3226 -0.7525
A4DAB037_6fxn_H_I 6fxn 100% -0.6963 6.5 4.0 -0.1636 -0.7703
A4DAB037_5y9j_H_L 5y9j 100% -0.729 6.5 4.0 -0.2865 -0.7902
A4DAB037_6fxn_O_P 6fxn 100% -0.719 6.5 4.0 -0.2509 -0.7843
A4DAB037_6fxn_Q_R 6fxn 100% -0.6947 6.5 4.0 -0.256 -0.7561
A4DAB037_6fxn_F_G 6fxn 100% -0.721 6.5 4.0 -0.2978 -0.7792
A4DAB037_6fxn_M_N 6fxn 100% -0.6973 6.5 4.0 -0.322 -0.7496